Activase Articles
Ischemic stroke continues to be a graveyard for drug development, says Decision Resources, but market will grow to $450 million in 2018
18 November 2009
Actilyse approved to clear CVAD occlusion
9 June 2008
Drug of benefit more than 3 hrs post stroke
3 March 2008
Acute ischemic stroke market is "graveyard" for drug R&D
6 August 2007
Boeh Ing's Actilyse gets nod from NICE
21 May 2007
FibroGen's FG-4539 reduces brain tissue damage in ischemic stroke
27 February 2006
CORRECTION: AstraZeneca's NXY-059 performs well in study
20 February 2006
AstraZeneca's NXY-059 performs well in study
20 February 2006
Positive Phase IIb findings for ReoPro
2 June 2003
Actilyse gets stroke indication in EU
3 February 2003
Genentech
20 January 2003
Genentech posts $214M loss in 2nd qtr
22 July 2002
Genentech full-year 2001 revenues increase 28%
28 January 2002
Genentech third-qtr revenues jump 24%
16 October 2001
Genentech third-qtr revenues jump 24%
12 October 2001
New use for alteplase cleared in USA
5 September 2001
Net income increases 28% at Genentech
12 July 2001
New world market forecasts from DR
6 April 2001
Genentech net income rises 30% for 2000
23 January 2001
Healthy harvest of New Chemical Entities in 2000
2 January 2001
Integrilin combination boosts artery patency
15 November 2000
BI wins positive opinion for Metalyse
10 November 2000
Genentech files sBLA for Activase catheter clearance
5 October 2000
B-MS focuses on intense growth and reveals product pipeline
2 October 2000
Genentech's TNKase shows one-year efficacy
30 August 2000
Lilly's ReoPro/stent better than Activase
11 August 2000
Genentech sales up 15%, but loss incurred
20 July 2000
Update - Genentech antibody for AMI disappoints
20 June 2000
FDA approves TNKase from Genentech
5 June 2000
Actelion: "promising" biotech/pharma firm
5 June 2000
World thrombotics market forecasts
3 May 2000
Alteplase use in stroke under fire again
2 March 2000
Healthy full-year results for many US pharmaceutical companies
27 January 2000
$180M lawsuit bill hits Genentech earnings
21 January 2000
Genentech's alteplase, no benefit after 3 hours
2 December 1999
COR's Integrilin plus thrombolytic in AMI
11 November 1999
Roche reducing stake in Genentech
11 October 1999
Antiplatelet/thrombolytic combination: way forward for MI therapy?
1 September 1999
Reteplase vs alteplase in pulmonary embolism
4 August 1999
Genentech files BLA for tenecteplase
3 August 1999
Genentech's 1st qtr product sales leap 42%
15 April 1999
Genentech reopens patent dispute with Centocor
11 February 1999
US Majors Post Strong Earnings For 3rd Quarter
15 October 1998
Genentech Pulls t-PA Stroke Study
22 July 1998
ECASS II: More Bad News For Thrombolysis In Stroke
16 July 1998
Rituxan Revenues Boost Genentech's 2nd Quarter
14 July 1998
Argatroban In Acute Myocardial Infarction
8 April 1998
Combining Drugs With Interventional Cardiology
8 April 1998
Genentech Files Suit Against Centocor
19 March 1998
Centocor Buys Retavase Rights For $335 Million
17 February 1998
Is tPA Harmful To Neurons?
10 February 1998
Strong Growth For US Drug Firms In 1997
28 January 1998
Saruplase Set For Spring 1998 Launch
25 November 1997
Lanoteplase Tested In InTIME 2 Study
25 November 1997
ReoPro As Adjunct To Thrombolysis; TIMI 14
20 November 1997
3rd Qtr Sales And Earnings Take A Dip At Genentech
16 October 1997
New Studies At European Cardiology Meeting
15 September 1997
Solid Growth For US Firms Despite Strong $
24 July 1997
Roche/Corange Deal Comfirms Global Strategy
9 June 1997
Genentech's New tPA To Start Phase III
12 May 1997
Earnings Decline At Genentech In 1st Qtr
21 April 1997
GUSTO III: Activase Fends Off Retevase Challenge
20 March 1997
Positive Verdict On Roche's Posicor From FDA Panel
10 March 1997
US 4th Qtr/Year-End Results See Strong Growth
27 January 1997
BM Launches Retavase In USA
13 January 1997
Product News In 1996 Dominated By CNS
23 December 1996
First Launch Of Reteplase Follows EU/US Approvals
11 November 1996
AHA Issues Guidelines On tPA Use In Strokes
16 September 1996
Thrombolysis In Stroke; Bad News Follows Good
12 August 1996
Earnings Decline At Genentech In 2nd Qtr
22 July 1996
FDA Approves First Drug In USA For Ischemic Stroke
24 June 1996
Knoll's Ancrod Enters Pivotal Trial For Stroke
24 June 1996
Activase Gains Backing For Stroke Indication
17 June 1996
Genentech Files Suit Against Boeh Mannheim
3 June 1996
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
